Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
Br J Cancer
    January 2026
  1. ALRASHIDI M, Ferro F, Almohammadi A, Alyoubi NH, et al
    Efficacy and safety of low- and high-intensity focused ultrasound in glioblastoma: a systematic review of preclinical and clinical studies.
    Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03325.
    >> Share

    November 2025
  2. LIU H, Pan Z, Yang Q, Dai L, et al
    Insulin signalling-associated cell fate promotes neoplastic invasiveness in non-functioning pituitary gonadotroph adenoma via cis-regulatory elements activation.
    Br J Cancer. 2025;133:1454-1470.
    >> Share

    October 2025
  3. ERJAN A, Jamora K, Gutierrez E, Santiago A, et al
    Correction: Cumulative incidence and survival outcomes of brain metastases in sarcoma: a large single center retrospective analysis.
    Br J Cancer. 2025 Oct 16. doi: 10.1038/s41416-025-03176.
    >> Share

  4. FAN M, Wu X, Pan D, Du J, et al
    Multiscale Pancancer Analysis Uncovers Intrinsic Imaging and Molecular Characteristics Prominent in Breast Cancer and Glioblastoma.
    Br J Cancer. 2025 Oct 15. doi: 10.1038/s41416-025-03235.
    >> Share

  5. SAJWAN R, Wang L, Casar-Borota O, Karakostis K, et al
    A cancer-associated TP53 synonymous mutation induces synthesis of the p53 isoform p53/47.
    Br J Cancer. 2025;133:970-975.
    >> Share

    September 2025
  6. LEE H, Kim D, Kim B, Joung D, et al
    UDP-glucose ceramide glucosyltransferase promotes radioresistance via membrane reorganization to maintain redox balance in glioblastoma.
    Br J Cancer. 2025 Sep 22. doi: 10.1038/s41416-025-03191.
    >> Share

    July 2025
  7. GE Y, Yu M, Chang T, Wang Z, et al
    Predictive efficacy and role of 2HG in MGMT promoter methylation in gliomas: a retrospective study based on MRS and mediator variable analysis.
    Br J Cancer. 2025 Jul 30. doi: 10.1038/s41416-025-03132.
    >> Share

  8. ERJAN A, Jamora K, Gutierrez E, Santiago A, et al
    Cumulative incidence and survival outcomes of brain metastases in sarcoma: a large single center retrospective analysis.
    Br J Cancer. 2025 Jul 26. doi: 10.1038/s41416-025-03111.
    >> Share

  9. TANG S, Qu C, Zhang M, Zhou P, et al
    Novel mutations of SRPX facilitate the stemness and malignant progression of glioma.
    Br J Cancer. 2025 Jul 15. doi: 10.1038/s41416-025-03091.
    >> Share

  10. LU VM, Chandar JS, Castro JR, Seetharam D, et al
    Elucidating the association between TLR-4 expression and the clinical course of glioblastoma leptomeningeal disease.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03094.
    >> Share

    June 2025
  11. YANG R, Wang M, Zhang G, Bao Y, et al
    Correction: E2F7-EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression.
    Br J Cancer. 2025 Jun 20. doi: 10.1038/s41416-025-03057.
    >> Share

    May 2025
  12. ZHANG Z, Jin X, Yin Q, Li P, et al
    Cyst fluid ctDNA as a biomarker for genetic profiling and treatment monitoring in cystic brain metastases.
    Br J Cancer. 2025 May 29. doi: 10.1038/s41416-025-03047.
    >> Share

    April 2025
  13. WANG Z, Zou P, Chen Z, Hou J, et al
    Novel strategy to target glioblastoma-initiating cells using a braintropic adeno-associated virus carrying a miR-dependent genome-editing system.
    Br J Cancer. 2025 Apr 12. doi: 10.1038/s41416-025-03007.
    >> Share

  14. PU Y, Xu F, He A, Li R, et al
    Repurposing chlorpromazine for the treatment of triple-negative breast cancer growth and metastasis based on modulation of mitochondria-mediated apoptosis and autophagy/mitophagy.
    Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02992.
    >> Share

    March 2025
  15. STRASSHEIMER F, Elleringmann P, Ludmirski G, Roller B, et al
    CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma.
    Br J Cancer. 2025 Mar 18. doi: 10.1038/s41416-025-02977.
    >> Share

  16. STEINDL A, Zach C, Berchtold L, Grisold A, et al
    Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.
    Br J Cancer. 2025 Mar 1. doi: 10.1038/s41416-025-02967.
    >> Share

    October 2024
  17. SERRA R, Smith SJ, Rowlinson J, Gorelick N, et al
    Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma.
    Br J Cancer. 2024 Oct 22. doi: 10.1038/s41416-024-02878.
    >> Share

    September 2024
  18. ZHANG ZS, Gao ZX, He JJ, Ma C, et al
    Andrographolide sensitizes glioma to temozolomide by inhibiting DKK1 expression.
    Br J Cancer. 2024 Sep 12. doi: 10.1038/s41416-024-02842.
    >> Share

  19. SEIBOLDT T, Zeiser C, Nguyen D, Celikyurekli S, et al
    Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.
    Br J Cancer. 2024;131:763-777.
    >> Share

    August 2024
  20. ROA P, Foglizzo V, Harada G, Repetto M, et al
    Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Br J Cancer. 2024;131:601-610.
    >> Share

    June 2024
  21. QI L, Du Y, Huang Y, Kogiso M, et al
    CD57 defines a novel cancer stem cell that drive invasion of diffuse pediatric-type high grade gliomas.
    Br J Cancer. 2024 Jun 4. doi: 10.1038/s41416-024-02724.
    >> Share

    May 2024
  22. YANG L, Yi J, He W, Kong P, et al
    Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 May 25. doi: 10.1038/s41416-024-02673.
    >> Share

    February 2024
  23. CAO Q, Hajosch A, Kast RE, Loehmann C, et al
    Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
    Br J Cancer. 2024 Feb 23. doi: 10.1038/s41416-024-02608.
    >> Share

  24. CHIANG JY, Wei ST, Chang HJ, Chen DC, et al
    ABCC4 suppresses glioblastoma progression and recurrence by restraining cGMP-PKG signalling.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02581.
    >> Share

  25. PRETE AA, Angerilli V, Bergamo F, Vettore V, et al
    HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-023-02569.
    >> Share

  26. MOGENSEN H, Tettamanti G, Frederiksen LE, Talback M, et al
    Educational attainment in survivors of childhood cancer in Denmark, Finland, and Sweden.
    Br J Cancer. 2024;130:260-268.
    >> Share

  27. FLECCHIA C, Auclin E, Alouani E, Mercier M, et al
    Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
    Br J Cancer. 2024;130:442-449.
    >> Share

    January 2024
  28. HEYMER EJ, Hawkins MM, Winter DL, Teepen JC, et al
    Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study.
    Br J Cancer. 2024 Jan 19. doi: 10.1038/s41416-024-02577.
    >> Share

  29. HALLAL SM, Tuzesi A, Sida LA, Xian E, et al
    Glioblastoma biomarkers in urinary extracellular vesicles reveal the potential for a 'liquid gold' biopsy.
    Br J Cancer. 2024 Jan 11. doi: 10.1038/s41416-023-02548.
    >> Share

  30. JOO JE, Chu YL, Georgeson P, Walker R, et al
    Intratumoral presence of the genotoxic gut bacteria pks(+) E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer.
    Br J Cancer. 2024 Jan 10. doi: 10.1038/s41416-023-02554.
    >> Share

    November 2023
  31. TRIVEDI R, Bhat KP
    Liquid biopsy: creating opportunities in brain space.
    Br J Cancer. 2023;129:1727-1746.
    >> Share

    October 2023
  32. THOMAS EM, Wright JA, Blake SJ, Page AJ, et al
    Advancing translational research for colorectal immuno-oncology.
    Br J Cancer. 2023;129:1442-1450.
    >> Share

    September 2023
  33. VANDERLINDEN A, Jones CG, Myers KN, Rominiyi O, et al
    DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells.
    Br J Cancer. 2023 Sep 30. doi: 10.1038/s41416-023-02454.
    >> Share

  34. CHENG S, McLaughlin JR, Brown MC, Al-Sawaihey H, et al
    Correction: Maternal and childhood medical history and the risk of childhood brain tumours: a case-control study in Ontario, Canada.
    Br J Cancer. 2023 Sep 13. doi: 10.1038/s41416-023-02415.
    >> Share

  35. HVIDTFELDT UA, Chen J, Rodopoulou S, Strak M, et al
    Long-term air pollution exposure and malignant intracranial tumours of the central nervous system: a pooled analysis of six European cohorts.
    Br J Cancer. 2023;129:656-664.
    >> Share

    August 2023
  36. NTAFOULIS I, Kleijn A, Ju J, Jimenez-Cowell K, et al
    Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
    Br J Cancer. 2023 Aug 24. doi: 10.1038/s41416-023-02402.
    >> Share

  37. ZHAN Y, Song Y, Qiao W, Sun L, et al
    Focused ultrasound combined with miR-1208-equipped exosomes inhibits malignant progression of glioma.
    Br J Cancer. 2023 Aug 14. doi: 10.1038/s41416-023-02393.
    >> Share

  38. PARK J, Shim JK, Lee M, Kim D, et al
    Classification of IDH wild-type glioblastoma tumorspheres into low- and high-invasion groups based on their transcriptional program.
    Br J Cancer. 2023 Aug 9. doi: 10.1038/s41416-023-02391.
    >> Share

    July 2023
  39. LOPEZ J, Lai-Kwon J, Molife R, Welsh L, et al
    A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
    Br J Cancer. 2023 Jul 24. doi: 10.1038/s41416-023-02356.
    >> Share

    June 2023
  40. ZHANG G, Zhu Q, Fu G, Hou J, et al
    Correction to: TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
    Br J Cancer. 2023 Jun 19. doi: 10.1038/s41416-023-02305.
    >> Share

    May 2023
  41. CHENG S, McLaughlin JR, Brown MC, Al-Sawaihey H, et al
    Maternal and childhood medical history and the risk of childhood brain tumours: a case-control study in Ontario, Canada.
    Br J Cancer. 2023 May 10. doi: 10.1038/s41416-023-02281.
    >> Share

  42. CROMIE KJ, Hughes NF, Milner S, Crump P, et al
    Socio-economic and ethnic disparities in childhood cancer survival, Yorkshire, UK.
    Br J Cancer. 2023;128:1710-1722.
    >> Share

    April 2023
  43. LYU L, Jiang Y, Ma W, Li H, et al
    Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-gamma-induced tumour-associated fibroblasts remodelling.
    Br J Cancer. 2023;128:1117-1133.
    >> Share

    March 2023
  44. KIANG KM, Tang W, Song Q, Liu J, et al
    Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma.
    Br J Cancer. 2023 Mar 17. doi: 10.1038/s41416-023-02225.
    >> Share

    February 2023
  45. WALLACE ND, Dunne MT, McArdle O, Small C, et al
    Efficacy and toxicity of primary re-irradiation for malignant spinal cord compression based on radiobiological modelling: a phase II clinical trial.
    Br J Cancer. 2023;128:576-585.
    >> Share

    September 2022
  46. ABIKO K, Hamanishi J, Matsumura N, Mandai M, et al
    Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".
    Br J Cancer. 2022 Sep 6. pii: 10.1038/s41416-022-01960.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016